Biotech RadarJobs updated

COMPANY

Silence Therapeutics

HQ: Hoboken, NJ source · silence-therapeutics.com ↗ · Europe

Clinical Phase 2

Keywords: RNA therapeutics siRNA Non-transfusion-dependent Thalassemia Low Risk Myelodysplastic Syndrome Polycythemia Vera Cardiovascular Diseases Atherosclerosis Lipoprotein(a) Hyperlipidemias Dyslipidemias Elevated Lp(a) Very-Low Risk Myelodysplastic Syndrome Pancreatic Ductal Carcinoma SLN124 SLN360 Atu027

Location: Hoboken, NJ · source · Oct 15, 2026

Profile checked Oct 10, 2026

$175.0MRaised (2 yrs)8Trials (company is sponsor)

Timeline

  1. Raise Follow-on offering: $175M (total, as published), announced Aug 11, 2026. Source: SEC filing. source ↗
  2. Trial start Phase 1/Phase 2: Study to Assess SLN124 in Patients With Polycythemia Vera source ↗
  3. Trial start Phase 2: Evaluate SLN360 in Participants With Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events source ↗
  4. Trial start Phase 1: A Study Investigate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Response of SLN124 in Adults With Alpha/Beta-thalassaemia and Very Low- and Low-risk Myelodysplastic Syndrom source ↗
  5. Trial start Phase 1: Study to Investigate Safety, Tolerability, PK and PD Response of SLN360 in Subjects With Elevated Lipoprotein(a) source ↗
  6. Trial start 1: A Phase 1 Study to Evaluate the Safety, Tolerability, PK and PD of SLN124 in Healthy Volunteers source ↗
  7. Trial start Phase 1: Study in Beta-thalassaemia or Myelodysplastic Syndrome Patients to Investigate the Safety and Tolerability of SLN124 source ↗
  8. Trial start Phase 1/Phase 2: Atu027 Plus Gemcitabine in Advanced or Metastatic Pancreatic Cancer (Atu027-I-02) source ↗
  9. Trial start Phase 1: Study With Atu027 in Patients With Advanced Solid Cancer source ↗

Funding

Raised: $175.0M. Last 2 years.

Clinical trials (lead sponsor) 8

RecordTitlePhaseStatusStartPrimary completion
NCT05499013Study to Assess SLN124 in Patients With Polycythemia VeraPhase 1/Phase 2Active, not recruitingJan 26, 20232026-09 (estimated)
NCT05537571Evaluate SLN360 in Participants With Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease EventsPhase 2CompletedDec 13, 2022Jan 11, 2024 (actual)
NCT04606602Study to Investigate Safety, Tolerability, PK and PD Response of SLN360 in Subjects With Elevated Lipoprotein(a)Phase 1CompletedNov 18, 2020Aug 23, 2023 (actual)
NCT04718844A Study Investigate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Response of SLN124 in Adults With Alpha/Beta-thalassaemia and Very Low- and Low-risk Myelodysplastic SyndromePhase 1CompletedApr 14, 2021May 23, 2023 (actual)
NCT04559971A Phase 1 Study to Evaluate the Safety, Tolerability, PK and PD of SLN124 in Healthy Volunteers1CompletedSep 3, 2020Mar 23, 2021 (actual)
NCT04176653Study in Beta-thalassaemia or Myelodysplastic Syndrome Patients to Investigate the Safety and Tolerability of SLN124Phase 1WithdrawnAug 20, 2019Sep 30, 2021 (estimated)
NCT01808638Atu027 Plus Gemcitabine in Advanced or Metastatic Pancreatic Cancer (Atu027-I-02)Phase 1/Phase 2Completed2013-032015-08 (actual)
NCT00938574Study With Atu027 in Patients With Advanced Solid CancerPhase 1Completed2009-062012-07 (actual)
Feedback